DelveInsight’s, “Idiopathic Pulmonary Fibrosis Pipeline Insight, 2022,” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in the Idiopathic Pulmonary Fibrosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
In the Idiopathic Pulmonary Fibrosis Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Idiopathic Pulmonary Fibrosis NDA approvals (if any), and product development activities comprising the technology, Idiopathic Pulmonary Fibrosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Key takeaways from the Idiopathic Pulmonary Fibrosis Pipeline Insight Report
- DelveInsight’s analysis presents Idiopathic Pulmonary Fibrosis Pipeline with 80+ active players in the domain investigating 80+ pipeline therapies.
- The leading Idiopathic Pulmonary Fibrosis Companies such as Mission Therapeutics, Lung Therapeutics, Theravance Biopharma, Pliant Therapeutics, Vicore Pharma, Galecto Biotech, FibroGen, Roche, Kinarus, Insmed, Avalyn Pharmaceuticals, Bridge Biotherapeutics, and others are developing potential drug candidates to improve the Idiopathic Pulmonary Fibrosis treatment scenario.
- Key Idiopathic Pulmonary Fibrosis pipeline therapies such as DUB program: USP30 Inhibitor, LTI-03, TD-1058, PLN-74809, C21, GB0139, Pamrevlumab, PRM-151, KIN001-IPF, Treprostinil palmitil, AP01, BBT-877, and others are under investigation in different phases of clinical trials for the treatment of Idiopathic Pulmonary Fibrosis.
- The companies and academics are working to assess challenges and seek opportunities that could influence Idiopathic Pulmonary Fibrosis R&D. The therapies under development are focused on novel approaches to treat/improve Idiopathic Pulmonary Fibrosis.
Request for Sample to know which pharma company is expected to be at the forefront in the coming years @ Idiopathic Pulmonary Fibrosis Pipeline Outlook
Idiopathic Pulmonary Fibrosis Overview
Idiopathic Pulmonary Fibrosis (IPF) is a rare, chronic, progressive fibrosing interstitial pneumonia that is found to affect the middle-aged and older adults; and affects lung tissue (alveoli in particular) by either thickening, stiffening, or persistent and progressive scarring (fibrosis) which increases irreversibly over time. If an individual has IPF, scarring affects the air sacs, limiting the amount of oxygen that gets into the blood. With less oxygen in the blood, one can get breathlessness from everyday activities, like walking. This group of lung disorders is also known as ‘Diffuse Parenchymal Lung Diseases,’ which is characterized by a broader umbrella of ‘Interstitial Lung Diseases (IDLs). Cause of IPF is still unknown; researchers postulate that the disease probably results from a combination of genetic and environmental factors. There exists a strong possibility that genetic changes increase a person’s risk of developing IPF and subsequent exposure to certain environmental factors that trigger the disease further. However, much is still unknown about this emerging field of study.
Recent Breakthroughs of Idiopathic Pulmonary Fibrosis Treatment Landscape
- In February 2022, Endeavor BioMedicines, announced the completion of a $101 million Series B financing, led by Ally Bridge Group and Avidity Partners. New investors participating in the round include Perceptive Advisors, Piper Heartland Healthcare Capital, Revelation Partners, funds managed by Tekla Capital Management LLC, and funds and accounts advised by T. Rowe Price Associates, Inc. Existing investors Omega Funds and Longitude Capital also participated. Proceeds will support the advancement of Endeavor’s pipeline programs, including ENV-101 (taladegib), a small molecule inhibitor of the PTCH1 receptor in the Hedgehog signaling pathway for the treatment of cancer and idiopathic pulmonary fibrosis (IPF), as well as ENV-201, a potentially best-in-class small molecule inhibitor of ULK1/2 for the treatment of KRAS-driven cancers.
- In October 2021, Agomab Therapeutics NV entered into a definitive agreement under which it will acquire Origo Biopharma S.L., a Spanish clinical-stage biotechnology company developing organ-restricted small molecule drug candidates targeting the transforming growth factor beta (TGF-β) pathway for the treatment of fibrosis-related disorders.
- In September 2021, Syndax Pharmaceuticals, Inc. and Incyte entered into an exclusive worldwide collaboration and license agreement to develop and commercialize axatilimab, Syndax’s anti-CSF-1R monoclonal antibody. Syndax and Incyte are seeking to develop axatilimab as a backbone therapy for patients with cGVHD as well as in additional immune-mediated diseases where CSF-1R-dependent monocytes and macrophages are believed to contribute to organ fibrosis
- In April 2021, Syndax Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to axatilimab, its anti-CSF-1R monoclonal antibody, for the treatment of patients with idiopathic pulmonary fibrosis (IPF).
Request a sample and discover the recent advances in Idiopathic Pulmonary Fibrosis Ongoing Clinical Trial Analysis and Medications, click here @ Idiopathic Pulmonary Fibrosis Treatment Landscape
Idiopathic Pulmonary Fibrosis Emerging Drugs
- PRM-151: Hoffmann-La Roche
- Pamrevlumab: FibroGen
- Tipelukast: MediciNova
- PLN-74809: Pliant Therapeutics
- GLPG4716: Galapagos NV
The idiopathic Pulmonary Fibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- Intravitreal
- Subretinal
- Topical
- Molecule Type
Scope of the Idiopathic Pulmonary Fibrosis Pipeline Insight Report
- Coverage- Global
- Idiopathic Pulmonary Fibrosis Pipeline Assessment by Product Type
- Idiopathic Pulmonary Fibrosis Pipeline Assessment by Stage and Product Type
- Idiopathic Pulmonary Fibrosis Pipeline Assessment by Route of Administration
- Idiopathic Pulmonary Fibrosis Pipeline Assessment by Stage and Route of Administration
- Idiopathic Pulmonary Fibrosis Pipeline Assessment by Molecule Type
- Idiopathic Pulmonary Fibrosis Pipeline Assessment by Stage and Molecule Type
- Idiopathic Pulmonary Fibrosis Pipeline Companies- Mission Therapeutics, Lung Therapeutics, Theravance Biopharma, Pliant Therapeutics, Vicore Pharma, Galecto Biotech, FibroGen, Roche, Kinarus, Insmed, Avalyn Pharmaceuticals, Bridge Biotherapeutics, and others
- Idiopathic Pulmonary Fibrosis Pipeline Therapies- DUB program: USP30 Inhibitor, LTI-03, TD-1058, PLN-74809, C21, GB0139, Pamrevlumab, PRM-151, KIN001-IPF, Treprostinil palmitic, AP01, BBT-877, and others
Table of content
- Introduction
- Executive Summary
- Idiopathic Pulmonary Fibrosis: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Idiopathic Pulmonary Fibrosis – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- PRM-151: Hoffmann-La Roche
- Mid Stage Products (Phase II)
- Tipelukast: MediciNova
- Early Stage Products (Phase I/II)
- Lung stem cells: Regend Therapeutics
- Early Stage Products (Phase I)
- LTI-03: Lung Therapeutics
- Preclinical and Discovery Stage Products
- AD-214: Adalta
- Inactive Products
- Idiopathic Pulmonary Fibrosis Key Companies
- Idiopathic Pulmonary Fibrosis Key Products
- Idiopathic Pulmonary Fibrosis- Unmet Needs
- Idiopathic Pulmonary Fibrosis- Market Drivers and Barriers
- Idiopathic Pulmonary Fibrosis- Future Perspectives and Conclusion
- Idiopathic Pulmonary Fibrosis Analyst Views
- Idiopathic Pulmonary Fibrosis Key Companies
- Appendix
Got Queries? Find out the related information on Idiopathic Pulmonary Fibrosis Mergers and acquisitions, Idiopathic Pulmonary Fibrosis Licensing Activities @ Idiopathic Pulmonary Fibrosis Emerging Drugs, and Recent Trends
Related Reports- Stem Cell Market | Asperger Syndrome Market
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services